Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) COO Margaret A. Horn sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $32.08, for a total value of $160,400.00. Following the completion of the sale, the chief operating officer now directly owns 99,474 shares in the company, valued at approximately $3,191,125.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Revolution Medicines Price Performance
Shares of NASDAQ RVMD traded up $0.07 during midday trading on Tuesday, hitting $31.00. The stock had a trading volume of 1,343,380 shares, compared to its average volume of 1,105,024. The firm has a market cap of $3.38 billion, a P/E ratio of -9.97 and a beta of 1.36. Revolution Medicines, Inc. has a fifty-two week low of $17.03 and a fifty-two week high of $35.50. The company’s 50-day simple moving average is $30.04 and its 200 day simple moving average is $26.17.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last issued its earnings results on Tuesday, August 8th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.10). The business had revenue of $3.82 million during the quarter, compared to the consensus estimate of $1.56 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative return on equity of 36.46%. The firm’s revenue for the quarter was down 58.1% compared to the same quarter last year. During the same period last year, the business posted ($0.82) EPS. Equities analysts expect that Revolution Medicines, Inc. will post -3.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
RVMD has been the topic of a number of research reports. Oppenheimer boosted their price objective on Revolution Medicines from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Revolution Medicines in a report on Wednesday, August 2nd. Finally, Needham & Company LLC reduced their price target on shares of Revolution Medicines from $35.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, August 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $33.67.
Revolution Medicines Company Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors.
- Five stocks we like better than Revolution Medicines
- Dividend Payout Ratio Calculator
- Hold-It-Forever AutoZone Pulls into Buy Zone
- What is ChatGPT Stock? How to Invest in It
- Virtual Riches: 3 Stocks Leading the VR Revolution
- Dividend Tax Calculator
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.